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Abstract
Background: In the present study, we report on a couple who underwent prenatal genetic diagnosis for
autosomal recessive polycystic kidney disease (ARPKD).
Case presentation: This healthy couple had previously had a healthy boy but had experienced two consecutive
neonatal deaths due to respiratory distress resulting from pulmonary hypoplasia caused by oligohydramnios. The woman
consulted our facility after she realized she was pregnant again. We promptly performed a carrier test for the PKHD1 gene
by target exome sequencing of samples from the couple. A pathogenic mutation was identified only in the paternal
allele (c.9008C>T, p.S3003F). The mutation was confirmed by Sanger sequencing of the DNA from formalin-fixed,
paraffin-embedded, kidney tissue of the second neonate patient and was not found in the healthy sibling. We then
performed haplotype analyses using microsatellite markers scattered throughout the PKHD1 gene. DNA from the
amniocentesis was determined to belong to a carrier, and the couple decided to continue with the pregnancy, obtaining
a healthy newborn. Subsequent detailed examination of the exome data suggested higher read depth at exons 45 and
46. Multiplex ligation-dependent probe amplification allowed identification of duplication of these two exons. This case
suggests the potential usefulness of target exome sequencing in the prenatal diagnosis of the PKHD1 gene in ARPKD.
Conclusions: This is the first report of intragenic duplication in the PKHD1 gene in ARPKD.
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Background
Autosomal recessive polycystic kidney disease (ARPKD) is
recognized as a severe hereditary form of polycystic kidney
disease [MIM 263200]. Patients present with enlarged kid-
neys with dilatations of the collecting ducts and congenital
hepatic fibrosis. Severely affected neonates have oligohy-
dramnios and pulmonary hypoplasia that cause respiratory
distress in the perinatal period. Approximately 30 % of af-
fected children die within the first year of life [1]. Survivors
of the perinatal respiratory insufficiency and cases with
later onset generally progress to end-stage renal disease
before adulthood. A minority of patients come to medical
attention in adulthood with liver-related complications and
mild kidney disease. ARPKD is a rare disorder that
affects ~1 in 20,000 live births.
ARPKD is caused by mutations in the PKHD1 gene,
chromosomally located at 6p12.2 [2, 3]. The PKHD1
gene is mainly expressed in the kidneys and liver, as well
as the pancreas. The encoded fibrocystin/polyductin protein
is a receptor-like transmembrane protein that localizes at
primary cilium, particularly at the basal body of the cilium,
and possibly functions as the sensory antenna in renal epi-
thelial cells or biliary duct cells [4]. Biallelic truncating mu-
tations or pathogenic missense mutations are identified in
most ARPKD cases [5]. The PKHD1 gene is considered the
only gene with mutations causally associated with ARPKD.
The carrier test for ARPKD has conventionally been
performed by Sanger sequencing of the PKHD1 gene.
However, this process is laborious and time-consuming
because the PKHD1 gene is a large gene spanning a 470-kb
genomic region and consisting of 86 exons, including alter-
natively spliced exons [2, 3]. In prenatal diagnosis, each
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mutation of the carrier parents needs to be determined
within a short period. Denaturing high-performance liquid
chromatography is one sequencing option to reduce
time and cost, although it is difficult to find the condi-
tions for optimal sensitivity [6, 7]. Recent advances in
next-generation sequencing have allowed PKHD1 muta-
tions to be screened with exome sequencing [8]. In our
present report, we describe carrier testing using target
exome sequencing performed for prenatal diagnosis. In
addition, we report a rare intragenic duplication in the
PKHD1 gene in ARPKD.
Methods
Human samples
In this study, we used genomic DNA samples from mem-
bers of a Japanese family with ARPKD siblings (Fig. 1).
After informed consent was provided, peripheral blood
samples were obtained. Genomic DNA was purified by
QuickGene-610 L (Fuji Film). In addition, we extracted
DNA from formalin-fixed, paraffin-embedded (FFPE), kid-
ney tissue from one of the ARPKD neonatal patients with
the aid of QIAamp DNA FFPE Tissue (Qiagen). This study
was approved by the Ethical Review Board for Human
Genome Studies of Fujita Health University (accession
number 13-14; approved on September 24, 2013).
Next-generation sequencing
For target exome sequencing, libraries were prepared
using the TruSight Rapid Capture kit (Illumina) according
to the manufacturer’s specifications. After tagmentation
with transposase, the libraries were amplified to add indi-
ces and common adapters for subsequent cluster gener-
ation and sequencing. The libraries were quantified by a
2100 Bioanalyzer (Agilent Technologies) using the High
Sensitivity DNA Kit (Agilent Technologies, 5067–4626).
Next, exon capture was performed using a TruSight
Inherited Disease Panel (Illumina, TG141–1005). Prior
to cluster generation, the libraries were further quantified
by Qubit (Invitrogen, Q32866) using the Qubit dsDNA
HS Assay Kit (Invitrogen, Q32851). Finally, the prepared
library was loaded on an Illumina MiSeq clamshell-style
cartridge for paired-end sequencing (Illumina). The data
were analyzed with the aid of Variant Studio for filtering
and annotation (Illumina). The reads were reanalyzed for
copy number alterations using the Comparative Exome
Quantification analyzer CEQer [9].
Microsatellite analyses
A total of seven microsatellite markers were selected based
on previous reports (Table 1) [10, 11]. Forward primers
were labeled with FAM. The PCR products were analyzed
by capillary electrophoresis (ABI3730 Genetic Analyzer;
Applied Biosystems).
Multiplex ligation-dependent probe amplification
Multiplex ligation-dependent probe amplification (MLPA)
probe pairs for the PHKD1 gene were used (SALSA MLPA
probe mix P341/P342; MRC-Holland, Amsterdam, the
Netherlands). In this approach, the MLPA probes consist
of two oligonucleotides, each containing a PCR primer se-
quence and a variable length sequence complementary to
the target. Genomic DNA was denatured (1 min at 98 °C)
and subsequently hybridized to the MLPA probe pairs
in accordance with the manufacturer’s protocol. After
ligation, probe pairs were amplified using universal
primers. The multiplex PCR products were then separated
on a capillary sequencer (ABI3730 Genetic Analyzer).
PCR amplification of the junction fragments
To isolate junction fragments, PCR was performed using
ExTaq (TaKaRa, Shiga, Japan). The PCR conditions were
35 cycles of 10 s at 98 °C and 3.5 min at 60 °C. PCR
primers were designed using sequence data from the
human genome database. The following primers were
used for amplification: PKHD1_Ex45F, 5′-CAAACTGT
GA AGCTCTGGAA CAGAG-3′, and PKHD1_Ex46R,
5′-GCAAATACTT CAGTTACTGA CAGC-3′. The
resulting PCR products were checked on 1 % agarose
gels. To obtain smaller PCR products, PCR was per-
formed with the following primers: PKHD1_Intron44,
5′-GCACAGGAAC ATCACCCAAT CTCCAAC-3′, and
PKHD1_Intron46-2, 5′-CGGTGCTGTT TACCGTACCC
TC-3′. The PCR conditions were 35 cycles of 10 s at 98 °C,
30 s at 60 °C, and 30 s at 72 °C. The PCR products were
subjected to ExoSAP-IT digestion (Affymetrix) and then
sequenced bidirectionally by capillary electrophoresis
(ABI3730 Genetic Analyzer). Breakpoint sequences were
characterized using RepeatMasker (http://www.repeatmas-
ker.org/) and non-B DB (https://nonb-abcc.ncifcrf.gov/
apps/site/default).
Case presentation
A healthy couple, both 23 years old, consulted our facil-
ity after they noticed their fifth pregnancy at 4 weeks of
gestation. Their first pregnancy was uncomplicated, and
Fig. 1 Family pedigree of the ARPKD family
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they had a healthy boy (Fig. 1). The second pregnancy
was complicated by oligohydramnios. At 1 week before
the due date, the woman vaginally delivered a boy, who
died at the second day after birth from respiratory dis-
tress due to pulmonary hypoplasia. The woman subse-
quently got pregnant and the pregnancy was again
complicated by oligohydramnios. At 1 month before the
due date, the woman delivered a girl via Caesarian section
due to breech presentation, who also died at the second
day after birth due to respiratory distress. An autopsy was
performed and multiple cysts were observed in both the
liver and kidneys. The neonate was thus diagnosed with
ARPKD. The fourth pregnancy ended in an early preg-
nancy loss. Soon after they noticed the fifth pregnancy,
they consulted our facility to undergo prenatal genetic
testing for ARPKD. The couple was screened by abdom-
inal ultrasound and no polycystic kidney disease was
observed.
Consent
Written informed consent was obtained from the patient
for publication of this manuscript and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.
Results
Carrier testing by target exome sequencing
We performed carrier testing using target exome sequen-
cing of genomic DNA only from both parents because the
DNA of the proband obtained from the FFPE sample was
too degraded to produce unbiased sequence data. A mis-
sense mutation, c.9008C>T (p.S3003F), was identified in
exon 58 of the PKHD1 gene in the paternal genome. Sanger
sequencing was performed and the presence of the muta-
tion was confirmed (Fig. 2). The DNA from the FFPE tissue
also carried the p.S3003F mutation, whereas the mother
and healthy sibling did not. This mutation has not been
reported in the human genomic database. The position of
the mutated amino acid is at the highly conserved region of
the extracellular domain just before the transmembrane
domain (phastCons = 0.901, cons score GERP = 5.67). The
SIFT score is 0 (deleterious) and PolyPhen 2 score is 0.984
(probably damaging), suggesting a pathogenic mutation.
On the other hand, no possible pathogenic mutation was
identified in the maternal genome.
Prenatal diagnosis by haplotype analyses
Since a maternal mutation was not identified, we decided
to perform prenatal diagnosis by haplotype analysis. We
selected seven microsatellite markers encompassing the
entire PKHD1 gene, including upstream and downstream
regions (Fig. 3a). By analyses of DNA from the parents, pro-
band, and the healthy sibling, the disease haplotype was
successfully determined (Fig. 3b). The healthy sibling was
found to be a carrier of the maternal disease haplotype. We
then performed an amniocentesis at 17 weeks of gestation.
The DNA isolated from amniotic fluid was analyzed for the
genotype of these microsatellite markers, and the results of
the typing showed that the fetus was a carrier of the
maternal disease haplotype but not of the paternal patho-
genic haplotype (Fig. 3b). The couple decided to continue
the pregnancy and finally obtained a healthy newborn.
Intragenic duplication identified by MLPA
We subsequently reanalyzed the target exome sequen-
cing data, focusing on read depth to identify deletion or
Table 1 PCR primers used for microsatellite analysis
Marker Forward primer (FAM) Backward primer
D6S465 GTCCAGAAGGGAATTTTCTACTCTTTG CTTTTCAATCATATAACTTTAAAAATGCC
3–204.2 k GCGTTGACCTATTTCTACACAG CTTAGGCAAATAAGACCTGGAGAGG
D6S1714 TGTATCCACTGCCATCACTT AGCACCAAATGACACAGAAC
D6S243 AATAGAACAAATTTGGCCTCTGG CATCCTTAGAATGAAAAATTACTCAGG
MBC-2 (D6S0919i) CATGAGGTGAGAGTGAGAAGAGC AAAGCCAGTTTCCTGACAC
D6S1344 AGCCCTGTGGTTATTTATGCTTCTC GGTTGTTCCTTCTCTGAACATGGCCC
5–326 k (D6S0460i) CCTACCCTCTAAAAGGATCTGGG CCCCACCTACCAACTCTGAATAAA
Fig. 2 Pathogenic nucleotide alteration of the PKHD1 gene identified in
the paternal allele. Sample names are indicated on the left: FHU14–046
(I-1, father), FHU13–047 (I-2, mother), FHU13–049 (II-1, healthy sibling),
FHU13–051 (II-3, proband), and FHU13–068 (II-5, amniotic fluid)
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duplication mutations in the maternal genome. The CEQer
algorithm revealed that the read depths of exons 45 and 46
were higher than those of other exons (Additional file 1:
Figure S1). We then performed MLPA for all exons of the
PKHD1 gene using genomic DNA from both parents as
well as a normal control. The amounts of PCR products
for exons 45 and 46 in maternal DNA were 1.5 times
higher than those from the father or normal control
(Fig. 4a). A similar finding was also observed in the DNA
from the healthy sibling. This duplication is not found in
the database of copy number variations. We considered
that the maternal mutation was a duplication of exons 45
and 46. If the duplication is a tandem repeat, it results in a
frameshift that produces a pathogenic C-terminally trun-
cated protein.
To analyze the breakpoint of this duplication at a nucleo-
tide resolution, we designed inversely oriented PCR
primers within both exons 45 and 46. Long-range PCR
using primers successfully yielded a PCR product that
incorporated the junction of the tandem duplication. Mul-
tiple PCR primers were then designed upstream and down-
stream of the putative breakpoint (introns 44 and 46) and
PCR-direct sequencing was performed (Fig. 4b). Sequence
analysis of the PCR product revealed the following:
rsa[hg19] 6p12.3(51,746,249–51,751,855) × 3. The proximal
and distal region was joined with a one-nucleotide micro-
homology (Fig. 4c).
We further analyzed the sequence around the prox-
imal and distal breakpoint regions. Both of the break-
points in introns 44 and 46 were located near the LINE1
element, whereas no substantial homology was found
between the breakpoint regions (data not shown). We
did not identify any non-B DNA motif that could have
induced replication fork stalling at either the proximal
or distal breakpoint regions [12].
Discussion
In our present study, we used target exome sequencing
as a carrier test for the prenatal diagnosis of ARPKD. In
ARPKD, genetic screening of the PKHD1 gene is typic-
ally performed by PCR amplification of all coding exons
followed by Sanger sequencing. This method is laborious
and time-consuming however because the PKHD1 gene
is a large gene spanning a 470-kb genomic region and
consisting of 86 exons, including alternatively spliced exons,
and recently new exons were identified further [2, 3, 13].
For prenatal diagnosis, each mutation of the carrier parents
needs to be determined within a short period. Target
exome sequencing can overcome these issues. Because the
sequence of all coding exons can be obtained within a
week, this strategy would be particularly useful when a car-
rier couple consults a medical facility for a prenatal diagno-
sis after they notice their pregnancy.
In ARPKD, genetic screening of the PKHD1 gene by
PCR-direct sequencing of all coding exons can identify
disease-causing mutations in up to 82 % of cases [14].
Since most mutations identified by this method are
nucleotide alterations, the remaining 18 % might carry
copy number mutations that can escape this screening.
One report has stated that MLPA screening did not iden-
tify any exon deletion/duplication mutation in 39 ARPKD
families [5]. Two previous case reports have described
multiple exon deletions in the PKHD1 gene [15, 16]. To
our knowledge, our current study is the first report of a
duplication mutation in the PKHD1 gene in a patient with
ARPKD. Quantitative analysis of the exome sequence data
Fig. 3 Microsatellite analysis of the disease haplotype. a Genomic structure of the region around the PKHD1 gene. Seven microsatellite markers
were used. The upper panel indicates a transcription map of this region with the name of the seven markers at the bottom. Physical distances
(middle panel) as well as genetic distances (lower panel) between the markers are indicated. The location of exons 45 and 46 (arrow) are
between MBC-2 and D6S1344. b Haplotype analysis of the family members. The numbers indicate the size of the PCR products
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provided a clue to the duplication which was successfully
identified by subsequent MLPA. Since target exome ana-
lysis may identify a mutation at a nucleotide resolution as
well as the copy number variation of the exons, target
exome sequencing could replace PCR-direct sequencing
or other related PCR-based screening techniques in the
near future.
The junction of the duplication showed one-nucleotide
identity between the breakpoints without extensive hom-
ology, suggesting that fork stalling and template switching
or microhomology-mediated breakage-induced replication
is a plausible mechanism its formation [17]. Since we
found no sequence motif susceptible to the formation of a
non-B structure, replication stalling might have occurred
in a sequence-independent fashion. It has also been specu-
lated that two introns are located at close proximity in the
nucleus at the timing of the replication stall in either of
the introns [18].
We identified the duplication junction at a nucleotide
resolution, which allowed us to detect the pathogenic
allele by simple PCR. In our current case, the duplica-
tion mutation was identified after the delivery of the
healthy newborn. However, if careful examination of
exome data had enabled the identification of both the pa-
ternal mutation and maternal duplication, we could have
performed prenatal diagnosis directly by detection of both
paternal and maternal mutations. In the case of an amnio-
centesis, the sample often contains a considerable amount
of dead cells that impede copy number analysis techniques
such as cytogenetic microarray and MLPA. The determin-
ation of the breakpoint would provide a simple PCR-
based diagnosis of the pathogenic allele. We thus conclude
that target exome sequencing of the PKHD1 gene has util-
ity as a carrier test for the prenatal diagnosis of ARPKD.
Conclusion
This case suggests the potential usefulness of target exome
sequencing in the prenatal diagnosis of the PKHD1 gene in
ARPKD. This is the first report of intragenic duplication in
the PKHD1 gene in ARPKD.
Additional file
Additional file 1: Figure S1. Quantitative analysis of the exome data
using the Comparative Exome Quantification analyzer (CEQer). The upper
panel indicates the map of the PKHD1 gene. The lower panel indicates
the normalized read depth. (TIFF 93 kb)
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Fig. 4 Exon duplication of the PKHD1 gene identified in the maternal allele. a Diagram of the MLPA results. Dark blue box, FHU14–046 (I-1, father); red
box, FHU13–047 (I-2, mother); green box, FHU13–049 (II-1, healthy sibling); purple box, FHU13–068 (II-5, amniotic fluid); light blue box, normal healthy
control. b Results of junction PCR analysis. Lane M, size markers; lane 1, FHU14–046 (I-1, father); lane 2, FHU14–047 (I-2, mother); lane 3, FHU13–049 (II-1,
healthy sibling); lane 4, FHU13–051 (II-3, proband); lane 5, FHU13–068 (II-5, amniotic fluid); lane 6, normal healthy control; lane 7, water control. c Results
of Sanger sequencing of the junction PCR product. The upper panel indicates the exon-intron structure around the junction
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